Shifting from Crisis Management to Health Maintenance

With an unparalleled approach, Vectorious’ V-LAP platform is emerging as the treatment choice for heart failure patients.

Physician-Directed Patient Self-Management Approach

Heart failure is a complex chronic disease. 33% of patients with heart failure (HF) are readmitted to the hospital within 90 days of discharge. Acute decompensation accounts for nearly 50% of these cases and causes pulmonary congestion.

The Vectorious platform is designed to enable optimal treatment of heart failure by providing the most accurate and earliest indication for congestion – using Left Atrial Pressure data.

Creating Better Clinical Outcomes

Early Detection

Remote daily monitoring of LAP data — the earliest and most accurate physiological indicator for congestion and heart failure deterioration.

Higher Adherence

Patients take an active role in disease management: the V-LAP patient app presents the last pressure readings, sends alerts, and guides patients on diuretics adjustments when LAP moves outside of the optimal thresholds.

Identify Comorbidities

Using sensitive automated supportive algorithms, high-resolution LAP waveforms allow physicians to diagnose additional cardiac comorbidities like mitral regurgitation, arrhythmias, diastolic dysfunction and more.

Decision Support System

Physicians make better decisions based on artificial intelligence that uses pattern recognition algorithms, to design optimal recovery plans.

Earliest and Most Specific Indication for Heart Failure

By tracking trends of left atrial pressure readings with the
V-LAP, physicians can detect heart failure decompensation before the onset of symptoms, change medications, and steer the patient away from further complications

Tracking In-heart Data

The V-LAP maps out heart failure decompensation based on mean left atrial pressure readings, so that physicians can detect impending HF exacerbation and act accordingly. Furthermore, physicians can drill down to daily high-resolution left atrial pressure waveform morphology, receiving input regarding common co-morbidities.

The increase of left atrial pressure is the most specific and earliest sign of impending heart failure exacerbation – long before clinical symptoms occur. V-LAP’s unmet clinical need has been evident for years, and the cardiology profession will benefit greatly from the availability of technology that can provide this valuable indication non-invasively on a daily basis.

William T. Abraham, MD

Ohio State University Medical Center Division of Cardiovascular Medicine, USA

The V-LAP system detected elevated mean LAP in one of our patients, so we adjusted medications until LAP was reduced to <20mmHg. Normally, we would increase diuretics for a period, but now we'll increase until we see LAP down to less than 16 in this patient. This is really useful!

Prof. Francisco Leyva-Leon

Cardiologist, Queen Elizabeth Hospital, Birmingham, UK

The V-LAP implantation was smooth and lasted only 6 minutes. We are now able to monitor the patient from home. I have direct access to his daily mean LAP variance and can remotely adjust his dosages when required.

Prof. Horst Sievert

Director of the CardioVascular Center Frankfurt, Germany

Vectorious’ V-LAP holds the potential of great promise for clinical use in Class III heart failure patients; with potential to improve quality of life, reduce mortality, and reduce rates of hospital admissions in this population.

Prof. Carlo Di Mario

Professor of Cardiovascular Medicine,
Careggi University Hospital, Florence, Italy

Thank you for subscribing!

Get our latest news and updates!

Subscribe to get Vectorious' Newsletter with the latest news and clinical updates from the VECTOR-HF study